Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

Abstract

BACKGROUND Many antihyperglycaemic drugs, including insulin, are primarily cleared by the kidneys, restricting treatment options for patients with kidney disease. Dulaglutide is a long-acting glucagon-like peptide-1 receptor agonist that is not cleared by the kidneys, and confers a lower risk of hypoglycaemia than does insulin. We assessed the efficacy and safety of dulaglutide in patients with type 2 diabetes and moderate-to-severe chronic kidney disease. METHODS AWARD-7 was a multicentre, open-label trial done at 99 sites in nine countries. Eligible patients were adults with type 2 diabetes and moderate-to-severe chronic kidney disease (stages 3-4), with an HbA1c of 7·5-10·5%, and who were being treated with insulin or insulin plus an oral antihyperglycaemic drug and were taking a maximum tolerated dose of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker. Participants were randomly assigned (1:1:1) by use of a computer-generated random sequence with an interactive response system to once-weekly injectable dulaglutide 1·5 mg, once-weekly dulaglutide 0·75 mg, or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks. Insulin glargine and lispro doses were titrated as per an adjustment algorithm; dulaglutide doses were masked to participants and investigators. The primary outcome was HbA1c at 26 weeks, with a 0·4% non-inferiority margin. Secondary outcomes included estimated glomerular filtration rate (eGFR) a…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(18)30104-9

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

13 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

The citation lists are queued

They are fetched later and appear here then.

References 30 · Cited by 648

Metadata

Authors
Tuttle, K. R., Lakshmanan, M. C., Rayner, B., Busch, R. S., Zimmermann, A. G., Woodward, D. B., & Botros, F. T.
Affiliations
  • University of Washington (US)
  • Eli Lilly (United States) (US)
  • University of Cape Town (ZA)
  • Albany Medical Center Hospital (US)
Corresponding author
Tuttle, Katherine R
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2018-08
Volume
6
Issue
8
Pages
605-617
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2808008353
Cited by
648
References
30
Citations by year
2026: 63 · 2025: 92 · 2024: 75 · 2023: 91 · 2022: 85 · 2021: 74 · 2020: 90 · 2019: 59 · 2018: 19
FWCI
47.84
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
dulaglutide, insulin glargine, type 2 diabetes, chronic kidney disease, GLP-1 receptor agonists, basal insulin therapy, insulin lispro, HbA1c, estimated glomerular filtration rate, albuminuria, non-inferiority, renal safety, dose titration, ACE inhibitors, angiotensin receptor blockers
MeSH terms
Insulin Glargine, Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemia, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Middle Aged, Prognosis, Recombinant Fusion Proteins, Severity of Illness Index, Biomarkers, Renal Insufficiency, Chronic, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. https://app.cochat.ai/papers/10.1016/s2213-8587(18)30104-9
The paper
Tuttle, K. R., Lakshmanan, M. C., Rayner, B., Busch, R. S., Zimmermann, A. G., Woodward, D. B., & Botros, F. T. (2018). Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(18)30104-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.